In first-line metastatic pancreatic ductal adenocarcinoma (mPDAC), Oncolytics's flagship pelareorep, an intravenously ...

A collaborative research team has successfully developed a novel fluorescent probe, SLY (Sialyl Lewis Yellow), capable of ...

Patients on baseline steroids had lower ORR, and markedly shorter PFS survival and OS compared with those not receiving ...

Sirtex Medical’s SIR-Spheres Y-90 resin microspheres receive US FDA nod to treat unresectable hepatocellular carcinoma: Woburn, Massachusetts Tuesday, July 8, 2025, 17:00 Hrs [I ...

Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, PeriNessCompany evaluating systemic recombinant human DNase I (DNase I) in ...

The FDA approves SIR-Spheres Y-90 microspheres for treating unresectable hepatocellular carcinoma, showcasing impressive ...

The FDA approved SIR-Spheres Y-90 resin microspheres for unresectable liver cancer, the only radioembolization approved in ...

Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary - As cancer rates climb ...

Sirtex Medical announced that the FDA has approved the company’s SIR-Spheres yttrium-90 (Y90) resin microspheres for the trea ...

Exelixis (EXEL) moves to 'Buy' with a de-risked pipeline, strong financials, and breakthrough phase 3 results. See more analysis here.

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide ( ) with these numbers expected to grow. The American Cancer Society ...

A new paper in BJS, published by Oxford University Press, indicates that early-onset gastrointestinal cancer rates are rising ...